Tactical Adaptations in Antibiotic Development for Virtual Biotechs

A virtual biotech company chose Covance to conduct two Phase III clinical trials for a new antibiotic treating life-threatening skin infections, such as methicillin-resistant staphylococcus aureus (MRSA). The Xcellerate® Protocol Design tool and Xcellerate® Site List Tool enabled Covance to identify optimal sites and high-performing investigators quickly, ensuring rapid selection and startup of appropriate sites and accelerated rate of patient enrollment which kept the trials on track and within budget.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/casestudies/Tactical-Adaptations-Antibiotic-CSCDS121.pdf